INVESTOR FACT SHEET October 2011 Lipocine Inc FACT SHEET as of July 1 2019 TICKER NASDAQ LPCN EXECUTIVE MANAGEMENT Dr Mahesh V Patel Chairman President amp CEO Morgan Brown EVP amp Chief Financial Officer ID: 773711
Download Presentation The PPT/PDF document "INVESTOR FACT SHEET" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
INVESTOR FACT SHEETOctober 2011 Lipocine Inc.FACT SHEET(as of July 1, 2019) TICKERNASDAQ: LPCNEXECUTIVE MANAGEMENT Dr. Mahesh V. PatelChairman, President & CEOMorgan BrownEVP & Chief Financial Officer FINANCIAL HIGHLIGHTSFully-Diluted Shares Outstanding (3/31/19)27.6 millionCash Balance (as of 3/31/19)$22.5 millionLong Term Debt$9.2 millionANALYST COVERAGE Dewey SteadmanCanaccord GenuityMatt KaplanLadenburg ThalmannOren LivnatH.C. Wainwright & Co.Dr. Cathy ReeceEmpire Asset Management CompanyJohn VandermostenZacks ResearchPRIMARY IR CONTACT Hans VitzhumLifeSci Advisors(646) 597-6979hans@lifesciadvisors.com Clinical-Stage Biopharmaceutical Company Focused on Metabolic and Endocrine Disorders TLANDO™ = Opportunity Product Pipeline Propriety Drug Delivery Platform
INVESTOR FACT SHEETOctober 2011 675 Arapeen Drive, Suite 202 Salt Lake City, Utah 84108 Phone: 801-994-7383 www.lipocine.comLPCN 1144: A Differentiated Oral NASH TherapyLPCN 1148: Oral Prodrug of Bioidentical Testosterone for the Treatment of NASH CirrhosisThis document contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and includes statements relating to the clinical status and potential uses and benefits of Lipocine’s product candidates. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including, without limitation, risks related to clinical trials, market acceptance, manufacturing and commercialization and other risks detailed in Lipocine’s filings with the U.S. Securities and Exchange Commission, all of which can be obtained on the Company’s website at www.lipocine.com or on the SEC website at www.sec.gov. The Company undertakes no duty to update or revise publicly any forward-looking statements contained in this document as a result of new information, future events or changes in the Company’s expectations.Clinical Relationship Between Testosterone and NAFLDAcross the full disease spectrum Potentially help patients survive longer while waiting for a liver transplant T levels positively correlate with muscle mass in men and modulates bone density, hemoglobin production, insulin resistance, and immunity , commonly impaired in cirrhosis 1 Testosterone therapy increased muscle mass in men with cirrhosis and low testosterone 2 Next Steps: Proof of Concept study in male NASH cirrhosis subjects